Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer

NCT03532087 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

NETWORK

Sponsor class

Stopped Due to new insights

Conditions

Breast Neoplasms

Interventions

DRUG: Denosumab 120 mg
DRUG: Denosumab 60 mg

Sponsor

Borstkanker Onderzoek Groep

Collaborators

[object Object]